002262 恩华药业
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入3,218,2506.91%5,911,1895,697,6335,041,5044,298,513
减:营业总成本2,364,7835.87%4,768,5464,403,8723,912,0193,358,817
    其中:营业成本841,16512.87%1,647,6161,506,5411,369,8431,020,461
               财务费用(5,648)-11.88%(16,991)(17,127)(19,261)(20,784)
               资产减值损失(22,748)133.09%(30,514)(39,070)(33,269)(16,189)
公允价值变动收益------------
投资收益35,91510.58%61,16065,56951,04436,273
    其中:对联营企业和合营企业的投资收益10,766178.65%14,81620,2899,6404,587
营业利润852,9567.58%1,199,1721,336,5741,182,3441,003,465
利润总额845,8197.28%1,173,0821,296,6881,168,644989,907
减:所得税费用105,51319.43%118,181155,896134,397109,819
净利润740,3065.75%1,054,9021,140,7921,034,247880,088
减:非控股权益(377)-14.36%(2,433)(2,772)(2,671)(20,622)
股东净利润740,6835.74%1,057,3341,143,5641,036,918900,709

市场价值指针
每股收益 (元) *0.7305.80%1.0501.1301.0300.890
每股派息 (元) *----0.4000.3600.3200.200
每股净资产 (元) *8.2619.42%7.9327.1846.3865.580
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容